NCT02179502 - First-in-Human Single and Multiple Dose of GLPG1690 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2014

Conditions

Healthy

Interventions

DRUG

GLPG1690 single ascending doses

Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg

DRUG

Placebo single ascending doses

Single dose, oral suspension or solid formulation matching placebo

DRUG

GLPG1690, multiple ascending doses, oral suspension

Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg

DRUG

Placebo, multiple ascending doses, oral suspension

Multiple doses, daily for 14 days, oral suspension matching placebo

Trial Locations (1)

SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp